Patients in the immune-tolerant phase of hepatitis B virus infection benefit a lot from antiviral therapy
-
-
Key words:
- Hepatitis B virus /
- Hepatitis B, Chronic /
- Immune Tolerance /
- Therapeutics
-
[1] JIANG J, FAN P, CHEN SX, et al. Study of liver histopathology in 100 patients with chronic hepatitis B virus infection and with normal ALT levels[J]. J Clin Hepatol, 2009, 25(3): 180-181. http://lcgdbzz.org/article/id/LCGD200903008江军, 范平, 陈仕祥, 等. 100例丙氨酸氨基转移酶正常的慢乙肝病毒感染者的肝组织病理研究[J]. 临床肝胆病杂志, 2009, 25(3): 180-181. http://lcgdbzz.org/article/id/LCGD200903008 [2] GÖBEL T, ERHARDT A, HERWIG M, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe[J]. J Med Virol, 2011, 83(6): 968-973. DOI: 10.1002/jmv.22048. [3] CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65. [4] ILOEJE UH, YANG HI, SU J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology, 2006, 130(3): 678-686. DOI: 10.1053/j.gastro.2005.11.016.
本文二维码
计量
- 文章访问数: 437
- HTML全文浏览量: 164
- PDF下载量: 99
- 被引次数: 0